Logotype for Compass Minerals International Inc

Compass Minerals International (CMP) Q4 2025 earnings summary

Event summary combining transcript, slides, and related documents.

Logotype for Compass Minerals International Inc

Q4 2025 earnings summary

9 Dec, 2025

Executive summary

  • Fiscal 2025 marked a pivotal year with a narrowed net loss to $79.8 million from $206.1 million, driven by operational improvements, cost rationalization, and a back-to-basic strategy.

  • Adjusted EBITDA for the year was $198.8 million, down 4% year-over-year, but up 4% when excluding Fortress contingent consideration.

  • Net total debt reduced by 14% ($125 million) to $772.5 million, with successful refinancing extending debt maturities and enhancing liquidity.

  • Corporate cost rationalization, including workforce reductions and winding down the Fortress business, led to an 18% SG&A reduction.

  • Leadership and organizational changes aligned with operational improvement and profitability goals.

Financial highlights

  • Full-year revenue reached $1.25 billion, up 11% year-over-year; operating income was $25 million versus a $117 million loss.

  • Q4 operating earnings were $12 million, up from a $30 million loss last year; net loss improved to $7.2 million from $48 million.

  • Q4 Adjusted EBITDA rose to $42 million from $16 million year-over-year; full-year Adjusted EBITDA was $199 million.

  • Net cash provided by operating activities improved to $197.7 million from $14.4 million year-over-year.

  • Capital expenditures were $69.7 million, intentionally reduced due to a slow start to the deicing season.

Outlook and guidance

  • 2026 Adjusted EBITDA guidance: $200–$240 million; Salt segment: $225–$255 million; Plant Nutrition: $31–$36 million.

  • Salt sales volumes forecast to decline ~8% at midpoint, reflecting a return to typical winter assumptions, but margins expected to improve.

  • Plant Nutrition sales volumes expected to decline, but pricing and cost structure expected to improve.

  • Corporate overhead Adjusted EBITDA guidance: negative $56 million to negative $51 million, reflecting ongoing cost rationalization.

  • 2026 capital expenditures expected at $90–$110 million, returning to normal levels after a reduced 2025.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
All investor relations material. One API.
Learn more